Device Trial Radar · NCT07911527
The Edison™ System for Treatment of Renal Tumors Using Histotripsy (Histo-Renal Trial)
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Nov 1, 2026
Primary completion
Dec 31, 2028
Study completion Feb 28, 2029
Sponsor
- Lead sponsor
- Chinese University of Hong KongAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 2, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective single-center, single-arm, feasibility trial designed to evaluate the safety of the HistoSonics Histotripsy System for treatment of renal tumors. The type of design is exploratory and is considered interventional. Following histotripsy, subjects will undergo imaging ≤ 72 hours post-index procedure. Additionally, subjects will be followed at 1 month, 3 months, 6 months and 12 months timepoints.
Conditions
- Renal Tumors
Interventions
HistoSonics® Edison System (US)Device
Patient will be arranged to admit to the Chinese University of Hong Kong Medical Centre (CUHKMC), assessed by anaesthetist before the operation, and go through histotripsy treatment under general anaesthesia in CUHK Medical Centre (CUHKMC). After general anaesthesia with intubation, the patient is placed in left or right lateral position. A water tank will be placed on top of the patient's loin area. The histotripsy ultrasound and treatment head will be placed inside the water tank and image-guided histotripsy ablation of the kidney tumor will be performed. The overall anaesthesia time is estimated to be 60-75 minutes and ablation time is 10-20 minutes, respectively. The expected length of hospital stay is 1 day after operation. Patient will be followed up and assessed up to 1 year after the procedure.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary technique efficacyTime frame: at 90 days after treatment
- Primary safety endpointTime frame: at 30 days after the histotripsy procedure
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.